Rapid Micro Biosystems, Inc. (RPID) Income Statement
RPID 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRPID revenue and net income
Where RPID's revenue goes
2025Each bar shows an amount and its share of revenue. RPID kept −140.3% of revenue as net income.
RPID profit margins
RPID growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +19.7% | +25.2% | +15.9% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RPID quarterly EPS vs estimates
Rapid Micro Biosystems beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 6, 2026 (estimate $-0.20).
RPID income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M | $16.1M | $16.5M | $11.0M | $16.1M |
| Cost of revenue | $26.0M | $28.2M | $28.0M | $25.7M | $31.0M | $24.1M | $16.7M | $11.8M | $16.0M |
| Gross profit | $7.6M | −$109,000 | −$5.5M | −$8.5M | −$7.7M | −$8.1M | −$234,000 | −$813,000 | $59,000 |
| Research & development | $13.6M | $14.6M | $12.8M | $12.9M | $9.8M | $6.5M | $5.4M | — | — |
| Sales, general & admin | $34.8M | $35.2M | $38.3M | $41.8M | $29.7M | $15.9M | $13.0M | $2.5M | $1.8M |
| Total operating expenses | $55.0M | $49.8M | $51.1M | $54.7M | $39.5M | $22.5M | $18.4M | — | — |
| Operating income | −$47.4M | −$49.9M | −$56.6M | −$63.2M | −$47.2M | −$30.5M | −$18.6M | — | — |
| Interest income | $1.5M | $3.2M | $4.2M | $1.8M | — | — | — | — | — |
| Interest expense | $1.1M | $40,000 | — | $1.8M | $2.6M | $3.4M | $2.4M | $0 | $0 |
| Income before taxes | −$47.1M | −$46.9M | −$52.4M | −$61.4M | −$73.4M | −$36.9M | −$20.7M | — | — |
| Income taxes | $40,000 | $22,000 | $31,000 | −$576,000 | $91,000 | $134,000 | $427,000 | — | — |
| Net income | −$47.1M | −$46.9M | −$52.5M | −$60.8M | −$73.5M | −$37.1M | −$21.2M | — | — |
| EBITDA | −$42.7M | −$43.5M | −$49.3M | −$60.4M | −$69.3M | −$32.0M | −$16.9M | — | — |
| EPS (diluted) | −$1.07 | −$1.08 | −$1.22 | −$1.43 | −$21.44 | −$1.17 | −$0.67 | — | — |
| Gross margin | 22.7% | −0.4% | −24.4% | −49.8% | −33.3% | −50.2% | −1.4% | −7.4% | 0.4% |
| Operating margin | −141.1% | −178.0% | −251.2% | −369.0% | −203.3% | −190.0% | −112.9% | — | — |
| Net margin | −140.3% | −167.2% | −233.0% | −354.9% | −316.5% | −230.6% | −128.2% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.1M | $8.0M | $11.3M | $7.8M | $7.3M | $7.2M | $8.2M | $7.6M | $6.6M | $5.6M | $6.3M | $6.1M |
| Cost of revenue | $6.8M | $7.6M | $11.6M | $5.6M | $5.3M | $6.8M | $7.2M | $7.0M | $6.8M | $7.1M | $6.5M | $7.8M |
| Gross profit | $1.2M | $371,000 | −$329,000 | $2.3M | $1.9M | $404,000 | $981,000 | $622,000 | −$189,000 | −$1.5M | −$172,000 | −$1.6M |
| Research & development | $3.3M | $3.4M | $3.2M | $3.5M | $3.2M | $3.6M | $3.4M | $3.6M | $3.7M | $3.8M | $3.3M | $3.1M |
| Sales, general & admin | $10.2M | $10.9M | $8.7M | $8.5M | $9.2M | $8.4M | $7.8M | $9.1M | $9.4M | $8.9M | $8.7M | $9.7M |
| Total operating expenses | $13.5M | $14.2M | $11.9M | $13.6M | $14.1M | $12.1M | $11.2M | $12.7M | $13.2M | $12.8M | $12.0M | $12.8M |
| Operating income | −$12.3M | −$13.9M | −$12.2M | −$11.4M | −$12.1M | −$11.7M | −$10.2M | −$12.0M | −$13.4M | −$14.3M | −$12.2M | −$14.4M |
| Interest income | $140,000 | $256,000 | $321,000 | $347,000 | $351,000 | $466,000 | $575,000 | $768,000 | $838,000 | $983,000 | $983,000 | $1.0M |
| Interest expense | $646,000 | $639,000 | $809,000 | $417,000 | $12,000 | $12,000 | — | $11,000 | — | — | $992,000 | — |
| Income before taxes | −$12.9M | −$14.3M | −$12.5M | −$11.5M | −$11.8M | −$11.3M | −$9.7M | −$11.3M | −$12.6M | −$13.3M | −$11.2M | −$13.4M |
| Income taxes | $45,000 | $8,000 | $14,000 | $8,000 | $11,000 | $7,000 | −$9,000 | $13,000 | $15,000 | $3,000 | $8,000 | $10,000 |
| Net income | −$12.9M | −$14.3M | −$12.5M | −$11.5M | −$11.9M | −$11.3M | −$9.7M | −$11.3M | −$12.6M | −$13.3M | −$11.2M | −$13.4M |
| EBITDA | −$11.6M | −$12.9M | −$10.9M | −$10.3M | −$11.0M | −$10.4M | −$8.8M | −$10.5M | −$11.7M | −$12.5M | −$10.4M | −$12.6M |
| EPS (diluted) | −$0.27 | −$0.31 | −$0.28 | −$0.26 | −$0.27 | −$0.26 | −$0.22 | −$0.26 | −$0.29 | −$0.31 | −$0.26 | −$0.31 |
| Gross margin | 15.0% | 4.6% | −2.9% | 29.0% | 26.8% | 5.6% | 11.9% | 8.2% | −2.9% | −27.1% | −2.7% | −26.5% |
| Operating margin | −153.0% | −173.1% | −108.2% | −145.1% | −167.3% | −161.8% | −124.5% | −158.3% | −202.1% | −254.4% | −192.3% | −235.1% |
| Net margin | −160.5% | −178.4% | −110.8% | −146.8% | −163.3% | −156.3% | −117.6% | −148.9% | −190.1% | −237.4% | −176.3% | −217.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RPID's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RPID financial results
In fiscal year 2025 (ended December 31, 2025), Rapid Micro Biosystems reported revenue of $33.6 million, up 19.7% from the year before. It had a net loss of $47.1 million, a net profit margin of −140.3%. Diluted earnings per share came to −$1.07. Over five years revenue grew at an average rate of 15.9% a year.
See the RPID stock overview for the latest quote and news, or the RPID chart for price history and technical indicators.
RPID income statement FAQ
What is Rapid Micro Biosystems's annual revenue?
Rapid Micro Biosystems reported total revenue of $33.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 19.7% from $28.1 million the previous year.
Is Rapid Micro Biosystems profitable?
No. Rapid Micro Biosystems reported a net loss of $47.1 million in fiscal 2025, a net profit margin of −140.3%; its operating margin was −141.1%.
What is Rapid Micro Biosystems's gross margin?
Rapid Micro Biosystems's gross margin was 22.7% in fiscal 2025: for every $100 of revenue, Rapid Micro Biosystems kept $23 after the direct cost of its products and services.
How much does Rapid Micro Biosystems spend on research and development?
Rapid Micro Biosystems spent $13.6 million on research and development in fiscal 2025, 40.5% of revenue.
How fast is Rapid Micro Biosystems growing?
Revenue grew 15.9% a year on average over the last five fiscal years, from $16.1 million to $33.6 million.
What are Rapid Micro Biosystems's earnings per share?
Rapid Micro Biosystems earned $-1.07 per diluted share in fiscal 2025, compared with $-1.08 a year earlier.
When will Rapid Micro Biosystems report its next earnings?
Rapid Micro Biosystems is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens.
When does Rapid Micro Biosystems's fiscal year end?
Rapid Micro Biosystems's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.